Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer.
about
Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer.Novel diagnostic biomarkers for prostate cancer.Prognostic factors in prostate cancer.Epithelial-mesenchymal transition in prostate cancer is associated with quantifiable changes in nuclear structure.Quantitative characterization of preneoplastic progression using single-cell computed tomography and three-dimensional karyometryDevelopment of a nuclear morphometric signature for prostate cancer risk in negative biopsies.Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intentProstatic carcinoma: a multivariate analysis of prognostic factors.Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens.Nuclear morphometry, nucleomics and prostate cancer progressionProstatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate.Improved prediction of prostate cancer recurrence through systems pathology.Stereologically estimated mean nuclear volume of prostatic cancer is a reliable prognostic parameter.Nuclear features in oral squamous cell carcinoma: A computer-assisted microscopic study.Nuclear envelope irregularity is induced by RET/PTC during interphase.Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival.Does age influence the behaviour of localized prostate cancer?Detectable tumor cells in the blood and bone marrow: smoke or fire?Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.Structure and function analysis in circulating tumor cells: using nanotechnology to study nuclear size in prostate cancer.Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy.
P2860
Q33610863-2E378D33-E0D6-4FF0-8BFA-21DA2D46D1D8Q34231678-18567690-B3B1-4100-A1E4-7219208A6CDAQ34682069-6399CE52-75B8-4011-A7A5-A2CCAF78DA73Q34735292-9A74FFFB-465B-4910-8CE2-E759986033E5Q34747959-43FEBE6D-ABDC-4366-ADE1-16254173FAD5Q34902668-29F879F0-6C9F-40CE-B7AA-5EF6AFC7648AQ35966831-68018BAC-E6D9-41DF-8228-72A410751C5CQ35978450-83BAFACE-2A3E-4E1C-B87C-4F953B00230AQ36030759-FF9DD36A-9487-475E-9A3D-5B5193C33F12Q36194959-E3386176-B865-4A1E-B29F-D19C71C6937CQ38002780-C0847B0E-0778-408B-BA90-F405B81B2369Q41384548-A960CB7E-93B9-4D5D-A556-8045CC24F0A1Q41885944-6EDCD9F6-BED0-4222-8B6F-2B0F1DF039EBQ41894210-C1253070-271A-40EB-BC74-E4E6CC9CBE31Q42539824-BA3B5723-1717-4AAB-AAE6-CAE3ACFB7FC8Q42792243-D1D16CDD-7FD9-479F-A94A-0CA77EAEEB05Q43728397-E7D2B5A0-D611-426C-B2EB-4E38E7FD321CQ44098546-C4E87E0F-2CD5-4A19-993C-18105DEA1BACQ44199125-F53F513B-CB2F-4679-9B5C-53C61A565364Q47908321-71BA9057-C1A3-4358-AC51-C5ADEE83E91CQ48151896-A4088683-3B5C-4EA2-A436-7B795EDA58D8Q52581727-27F87463-E7C8-4E7E-98CF-B5F8595693E3Q53416801-A48CB877-3639-49EC-863E-1122DD2AC9DA
P2860
Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@en
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@nl
type
label
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@en
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@nl
prefLabel
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@en
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@nl
P2093
P1433
P1476
Use of nuclear morphometry, gl ...... patients with prostate cancer.
@en
P2093
Epstein JI
Piantadosi S
Pitcock RV
Steinberg GD
P304
P356
10.1002/1097-0142(19920701)70:1<161::AID-CNCR2820700126>3.0.CO;2-5
P407
P577
1992-07-01T00:00:00Z